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ttp://dx.doi.org/10.1016/j.ajpath.2013.11.024Solitary ﬁbrous tumors (SFTs) of the prostate are a rare type of spindle cell neoplasm that can
demonstrate either a benign or malignant phenotype. SFTs represent a clinical challenge along with
other spindle cell lesions of the prostate in terms of both diagnosis and treatment. The present study
shows, for the ﬁrst time, that SFTs of the prostate and other organs can comprise a mixed population of
ﬁbroblast, myoﬁbroblast, and smooth muscle cell types. The highly proliferative component demon-
strated a ﬁbroblastic phenotype that readily underwent myoﬁbroblast differentiation on exposure to
proﬁbrotic stimuli. Consistent with other recent studies, the prostatic SFTs demonstrated NAB2-STAT6
gene fusions that were also present in the ﬁbroblast, myoﬁbroblast, and smooth muscle cell types of the
SFT. The results of these studies suggest that benign and malignant prostatic tumors of mesenchymal
origin may be distinguished at the molecular and cellular levels, and that delineation of such
deﬁning characteristics may help elucidate the etiology and prognosis of such tumors. (Am J Pathol
2014, 184: 732e739; http://dx.doi.org/10.1016/j.ajpath.2013.11.024)This work was supported by NIH/NIDDK grant P20DK090770 (J.A.M.)
and by the Michigan Institute for Clinical & Health Research Clinical &
Translational Science Award (CTSA) grant UL1RR024986 (M.G.K.).
Disclosures: None declared.Solitary ﬁbrous tumors (SFTs) occur most commonly along
the pleura but may occur in a variety of extrathoracic sites,
including the genitourinary tract.1,2 SFTs represent a wide
spectrum of tumor types of mesenchymal origin that can
affect virtually any region of the body.3 SFTs are a type of
spindle cell tumor, a category that comprises diverse benign
and malignant tumors, including inﬂammatory myoﬁbro-
blastic tumors, smooth muscle tumors, stromal tumors of
uncertain malignant potential, stromal sarcomas, sarcoma-
toid carcinomas (carcinosarcoma), rhabdomyosarcoma, ex-
tensions of gastrointestinal stromal tumors from the adjacent
colon, and sclerosing adenosis, which may mimic spindle
cell tumors.4e12 Among spindle cell tumors involving the
prostate, SFTs represent one of the least common neo-
plasms, with 13 single cases and 9 series cases reported in
the literature.2,11e14 Although most SFTs are benign and
can be cured with surgery, 20% of SFTs will progress with
either local recurrence or distant metastases, which can be
difﬁcult to treat.3
SFTs of the prostate demonstrate a broad size distribution,
ranging from 2 to 14 cm, and commonly weigh between 100
and 170 g. They are likely derived from mesenchymal ﬁbro-
blastic cells, because immunohistochemistry generally revealsstigative Pathology.
.diffuse reactivity for CD34, vimentin, and bcl-2. SFTs have a
broad spectrum of histological features and, based on a com-
bination of pathological factors, including size, the number of
mitotic ﬁgures, nuclear pleomorphism, inﬁltrative boundaries,
and the presence of necrosis, pleura-based SFTs are distin-
guished as benign or malignant neoplasms.3e21 However,
these pathological factors do not always correlate with the
clinical behavior of the tumors, especially in the nonpleural
locations. Therefore, from a diagnostic, prognostic, and ther-
apeutic standpoint, SFTs remain a clinical challenge.
Recent studies identiﬁed the presence of a ubiquitousNAB2-
STAT6 gene fusion in both benign and malignant SFTs.22,23
This ﬁnding implies that SFTs may possess a unique biology
that distinguishes them from other spindle celletype tumors of
the prostate. The studies described here were designed to
explore SFT biology. To accomplish this, SFT tissue was
explanted, cultured in vitro, and the resulting cell cultures were
characterized and the proliferating cell types identiﬁed.
Complex Composition of Prostate SFTMaterials and Methods
Patient Characteristics and Course of Treatment
A 53-year-old man presented to emergency medicine with
gross hematuria and urinary retention. He had been previously
diagnosed with benign prostatic hyperplasia and self-reported
an American Urological Association Symptom Index score of
25 and quality of life score of 5. The patient was on medica-
tion, including Avodart (dutasteride) and Flomax (tamsulo-
sin), to relieve his lower urinary tract symptoms. The patient
underwent a routine 12-core needle biopsy for histological
evaluation of the prostate tissue, which was found to be
nonmalignant. However, the patient continued to experience
gross hematuria and underwent several rounds of bladder
irrigation to remove blood clots and assist with urinary void-
ing. To provide longer-term treatment of these symptoms, the
patient underwent prostatectomy, initially by holmium laser
enucleation of the prostate, which proved inefﬁcient, and then
by suprapubic cystostomy for tumor removal. The total vol-
ume of the resected prostate was >700 g. The patient subse-
quently self-reported an American Urological Association
Symptom Index of 2 and quality of life score of 0, consistent
with resolution of voiding dysfunction. Five additional SFT
tumors from the right lung of a 78-year-old woman (case 2),
left lung of a 55-year-old man (case 3), left inguinal soft tissue
of a 64-year-old man (case 4), pleura and chest wall of an 83-
year-old man (case 5), and pleura and chest wall of a 65-year-
old man (case 6) were also obtained for comparative purposes.
Histological Evaluation, Immunohistochemistry, and
Staining
Prostate tissues were ﬁxed in 10% phosphate-buffered
formalin, embedded in parafﬁn, sectioned, and then stained
with H&E. Immunohistostaining was performed on the Dako
Autostainer (Dako, Carpinteria, CA) using Dako LSABþ
and diaminobenzadine as the chromogen as described pre-
viously (25). Deparafﬁnized sections of formalin-ﬁxed tis-
sues at 5-mm thickness were labeled with primary antibodies
(CD99, CD34, bcl-2, desmin, progesterone receptor, pan-
keratinand S-100). Appropriate negative (no primary anti-
body) and positive controls were stained in parallel with each
set of tumors studied. The immunoreactivity was scored by a
four-tier (negative, low, moderate, or high) grading scheme.
Tissue sections from the index case 53-year-old male SFT
prostate, right lung of a 78-year-old woman, left lung of a 55-
year-old man, left inguinal soft tissue of a 64-year-old man,
pleura and chest wall of an 83-year-old man, and pleura and
chest wall of a 65-year-old man were subjected to Masson’s
trichrome staining as we have described previously.24
Collagen Content
Collagen content was determined using the methodology
described previously.25,26 Brieﬂy,Masson’s trichromeestainedThe American Journal of Pathology - ajp.amjpathol.orgtissue sections were digitally imaged using a PathScan Enabler
IV, and color segmented using a subprogram within MATLAB
version 7.10 (R2010a; MathWorks, Natick, MA) that separates
and quantiﬁes color elements from trichrome images, permit-
ting quantitation of blue-stained areas corresponding to extra-
cellular collagen. Using the area of a single tissue section as the
denominator, this approach provides a means to calculate the
portion of this area that is made up of mature extracellular
collagen I (the numerator), hence, the percentage of extracel-
lular collagen type I (numerator/denominator  100) in that
tissue section. By extension, this method also permits calcula-
tion of the percentage of the entire piece of tissue that ismade up
of mature extracellular collagen I.Prostate Tissue Explantation and Growth in Vitro
Prostate tissue was received from the operating room within
4 hours of resection in sterile 10% RPMI medium and
processed immediately for primary explant and culture as
previously described.27,28 Brieﬂy, tissue was minced into
pieces of <1 mm in size, digested overnight in 1 mg/mL
collagenase III (Worthington Biochemicals, Lakewood, NJ)
at 37C with gentle shaking, spun down, resuspended, and
then plated in 24-well plates with 5% HIE medium
comprising 5% fetal bovine serum (Life Technologies,
Grand Island, NY), Ham’s F12 Mediatech, Herndon, VA 5
mg/mL insulin, 10 ng/mL epidermal growth factor, 1 mg/mL
hydrocortisone (Sigma Chemical Co., St. Louis, MO), 0.05
mg/mL gentamicin (Life Technologies), and 0.5 mg/mL
fungizone (Cambrex Bioscience, Walkersville, MD) or in
deﬁned serum-free HIE medium supplemented with 5 mmol/
L ethanolamine (Sigma-Aldrich, St. Louis, MO), 10 mmol/L
HEPES (Sigma-Aldrich), 5 mg/mL transferrin (Sigma-
Aldrich), 10 mmol/L 3,30,5-triiodo-L-thyronine (Sigma-
Aldrich), 50 mmol/L sodium selenite (Sigma-Aldrich), 0.1%
bovine serum albumin (JRH Biosciences, Lenexa, KS), 0.05
mg/mL gentamicin (Life Technologies), and 0.5 mg/mL
fungizone (Cambrex Bioscience). Because one piece of tis-
sue was plated per well, it was possible to isolate cell pop-
ulations with differing morphologies as they grew out of the
tissue.Myoﬁbroblast Phenoconversion
Primary prostate stromal SFT ﬁbroblast cells or N1
immortalized prostate stromal ﬁbroblasts were grown to
70% conﬂuence, washed twice with PBS, and then grown
for 24 hours in serum-free HIE media.28 The cells were then
washed with additional serum-free HIE and treated with
vehicle [20 mmol/L citrate (pH 3.0)] or 5 ng/mL TGF-b1
(Cell Signaling Technology, Beverly, MA), or 0.1% bovine
serum albumin in PBS (vehicle) or 100 pmol/L CXCL5,
CXCL8, or CXCL12, or a combination of all three che-
mokines (R&D Systems, Minneapolis, MN) for 24 or 48
hours as previously described.27733
Figure 1 Histopathological and immunohistological analysis of pros-
tatic SFT tissue. A: Photomicrograph of H&E staining of SFT tissue section
demonstrating alternating hypocellular and hypercellular areas with spindle
cells in a collagenous background. BeD: Immunohistochemical analysis of
SFT tissue sections, demonstrating expression of Bcl-2 (B), CD99 (C), and
CD34 (D) proteins. Original magniﬁcation: 10 (A). Photomicrograph im-
ages were produced using a 40 objective (BeD).
Gharaee-Kermani et alImmunoﬂuorescence Assays
Primary prostatic SFT ﬁbroblasts, myoﬁbroblasts, and smooth
muscle cells were plated onto chamber slides coated with 10
mg/mL ﬁbronectin (Sigma-Aldrich). Cells were subjected to
immunoﬂuorescence as previously described using ﬂuorescein
isothiocyanateeconjugatedmousemonoclonal antiea-smooth
muscle actin (a-SMA), mouse monoclonal anti-calponin,
mouse monoclonal anti-vimentin (all from Sigma-Aldrich),
and biotin conjugated rabbit polyclonal anti-collagen type 1
(COL1) (Rockland Immunochemicals, Gilbertsville, PA),
PE-Cy5 streptavidin (BD Pharmingen, San Diego, CA), or
anti-mouse Alexa 568 (Invitrogen; Life Technologies, Carls-
bad, CA) secondary antibodies, and control mouse IgG2a
(Sigma-Aldrich), and rabbit IgG biotin conjugate (Rockland
Immunochemicals) (25). Immunoﬂuorescence to detect phos-
phorylated STAT6 was performed using the pSTAT6 Y641
primary antibody from Cell Signaling Technology (9361) and
an Alexa Fluor 594econjugated secondary goat antibody to
rabbit IgG from Life Technologies (A11037). Photomicro-
graphs were taken on an Olympus BX51 ﬂuorescence micro-
scope (Olympus, Tokyo, Japan).
Immunoblot, Protein Analysis, and Antibodies
Cells were lysed and proteins were puriﬁed as described
previously.28,29 Electrophoresis and immunoblotting were
performed using 30 mg of total protein extract, following
standard protocols. Total STAT6 and b-actin were detected
using a rabbit polyclonal antibody to STAT6 (9362S,
dilution 1:1500; Cell Signaling Technology) and a rabbit
monoclonal antibody to b-actin (4970, dilution 1:1500; Cell
Signaling Technology) with a goat antibody to rabbit sec-
ondary antibody (sc-2034; Santa Cruz Biotechnology,
Dallas, TX) at a 1:20,000 dilution.
Next-Generation Sequencing Library Preparation
Genomic DNA from frozen tissue was isolated using the
DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. Exome libraries
of genomic DNA were generated using the Illumina TruSeq
DNA Sample Prep kit (Illumina, San Diego, CA), following
the manufacturer’s instructions. Paired-end libraries were
sequenced with the Illumina HiSeq 2000 (2  100-nt read
length). Reads that passed the chastity ﬁlter of Illumina
BaseCall software (HCS 2.0, RTA 1.17) were used for sub-
sequent analysis. FastQC software version 0.10.1 was used to
assess sequence quality, and sequence alignment quality was
assessed using the Picard package version 1.106.22
Statistical Analysis
Averages and SDs were calculated and compared using two-
tailed Student’s t-tests. In all tests, P < 0.05 was considered
statistically signiﬁcant.734Results
Histopathological Diagnosis of SFT of the Prostate
Histopathological assessment of the prostate SFT tissue sec-
tions demonstrated hypercellular and hypocellular areas of
spindle cells intermixed with collagen (Figure 1A). Previous
studies have indicated that SFTs are generally positive for
CD34, bcl-2, CD99, and vimentin, but negative for CD117
(c-kit).3,10,15,21 Immunohistochemical evaluation of the pros-
tate SFT demonstrated that the tumor cells strongly expressed
CD34, bcl-2, and CD99 (Figure 1, BeD). Desmin and pro-
gesterone receptor were focally positive, whereas pankeratin
and S-100 were negative (data not shown). Taken together,
this staining pattern is consistent with a histodiagnosis of SFT.
SFT of the Prostate Comprises Fibroblast,
Myoﬁbroblast, and Smooth Muscle Cell Populations
SFT tissue was explanted, grown in culture, and then
evaluated morphologically and phenotypically. As shown in
Figure 2, cellular populations growing from individual
pieces of tissue demonstrated a mixed phenotype, with cells
from some pieces of tissue exhibiting an elongated, ﬁbro-
blastic morphology, some a more compact, myoﬁbroblastic
morphology, and some a smooth muscle cell phenotype.
Immunoﬂuorescence studies were pursued to accurately
assess the phenotypic characteristics of these cell populations.
Using four protein markersda-SMA, collagen I, vimentin,
and calponindit is possible to accurately characterize these
cell populations as primarily ﬁbroblastic, myoﬁbroblastic,
or smooth muscle (Figure 2A). As shown in Figure 2B,
cells that predominantly exhibited an elongated morphologyajp.amjpathol.org - The American Journal of Pathology
Figure 2 Characterization of prostatic SFT ﬁbroblastic, myoﬁbroblastic, and smooth muscle cell populations. A: Expected expression proﬁles for the a-SMA,
vimentin, calponin, and collagen I proteins in ﬁbroblast, myoﬁbroblast, and smooth muscle cell types. B: Photomicrographs depicting (left to right) tissue explants,
monolayer cell cultures, and immunoﬂuorescence staining for the proteins indicated. Cell nuclei were counterstained with DAPI (blue). Top row: Fibroblastic cells
demonstrated a spindle-shaped morphology and stained positive for vimentin and calponin and weakly positive for collagen I, but not a-SMA. Middle row:
Myoﬁbroblasts demonstrated a more compact morphology and stained positive for vimentin, a-SMA, and collagen I, but not calponin. Bottom row: Smooth muscle
cells demonstrated an elongated morphology and stained positive for a-SMA, calponin, and collagen I, but not vimentin. Original magniﬁcation: 40 (B).
Complex Composition of Prostate SFTcoexpressed vimentin and calponin and weakly expressed
collagen I, but not a-SMA, consistent with a ﬁbroblastic
phenotype. Alternatively, cells that coexpressed vimentin, a-
SMA, and collagen I, but not calponin, exhibited a more
compact morphology, consistent with a myoﬁbroblastic
phenotype.30,31 The identiﬁcation of myoﬁbroblast cells
indicated that SFTs contain a ﬁbrotic component, which may
account for the collagen strands observed in this and other
tumors of this type. Lastly, cells that coexpressed calponin,
a-SMA, and collagen I, but not vimentin, exhibited a long,
spindly shape, consistent with a smooth muscle phenotype.
SFTs Can Contain a High Collagen Content Consistent
with Tissue Fibrosis
The observation that the SFT prostate tissue contained a
myoﬁbroblast population promoted further exploration of
tissue ﬁbrosis within this and other SFTs. To examine this,
the SFT prostate and ﬁve SFTs from other tissue sources
were subjected to Masson’s trichrome staining and assessed
for collagen content. As seen in Figure 3A, the index SFT
prostate (case 1) and SFT tumors from the right lung of a 78-
year-old woman (case 2), left lung of a 55-year-old man (case
3), and pleura and chest wall of an 83-year-old man (case 5)
demonstrate high levels of blue staining, indicating high
collagen content compared to left inguinal soft tissue of a 64-
year-old man (case 4), and pleura and chest wall of a 65-year-
old man (case 6). Quantitation of tissue collagen content
conﬁrms this observation and shows that SFT tissues fromThe American Journal of Pathology - ajp.amjpathol.orgcases 1, 2, 3, and 5 demonstrate 50% collagen content,
whereas case 4 demonstrates 30% and case 6 demonstrates
15% collagen content (Figure 3B). The high level of collagen
content demonstrated by the majority of SFTs examined
suggests that collagen-secreting myoﬁbroblasts and smooth
muscle cells comprise a major component of these tumors.
The SFT Proliferative Cell Type Is Fibroblastic
The myoﬁbroblastic and smooth muscle phenotype cells
cultured from the prostatic SFT were viable for three pas-
sages in continuous culture, after which the cells no longer
proliferated. However, the ﬁbroblastic phenotype cells were
viable for >25 passages in continuous culture at the time of
the writing of this paper, demonstrating that the proliferative
cell type responsible for continued growth and expansion in
SFTs of the prostate is ﬁbroblastic rather than myoﬁbro-
blastic or smooth muscle.
Sequence Analysis of SFT of the Prostate Reveals a
NAB2-STAT6 Fusion
Sequence analysis of SFT prostate tissue genomic DNA
showed that the NAB2-STAT6 fusion, spanning hg19 co-
ordinates 57487380e57492860, was evident in >400
paired-end reads. As noted by Robinson et al,22 the number
of paired-end reads spanning the NAB2-STAT6 fusion
ranged from 25 to 4483 per case in 27 tumors exhibiting the
fusion by transcriptome sequencing. Therefore, the SFT735
Figure 3 Collagen content of SFTs. A: Tissue sections from six SFTs:
index prostate SFT (case 1), SFT from the right lung of a 78-year-old woman
(case 2), SFT from the left lung of a 55-year-old man (case 3), SFT from the
left inguinal soft tissue of a 64-year-old man (case 4), SFT from the pleura
and chest wall of an 83-year-old man (case 5), and SFT from the pleura and
chest wall of a 65-year-old man (case 6). Samples were subjected to
Masson’s trichrome staining. Blue color indicates collagen; red indicates
a-SMA. B: Quantitation of tissue collagen content.
Figure 4 NAB2-STAT6 fusion protein status in SFT prostate tissue and
derivative myoﬁbroblast (M), ﬁbroblast (F), and smooth muscle (SM) cells.
Protein was puriﬁed from the SFT prostate tissue and three derivative cell
populations, immunoblotted, and probed for STAT6. Red asterisks indicate
NAB2-STAT6 fusion proteins (at approximately 100 or approximately 150 kDa),
and red arrowheads indicatewtSTAT6. There is also someevidenceof additional
NAB2-STAT6 fusion proteins expressed by the three derivative cell populations
in the 100 to 150 kDa range. Although all samples were immunoblotted
together, the SFT prostate sample is shown at a darker exposure than the three
derivate cell population samples to demonstrate expression of wtSTAT6.
Gharaee-Kermani et alprostate examined here deﬁnitely demonstrated a NAB2-
STAT6 fusion. Moreover, the genomic coordinates of the
fusion conﬁrmed that it comprised an exon 6 NAB2 fused to
exon 18 of STAT6, the most common NAB2-STAT6 fusion
sequence previously described.22,23
Fibroblast, Myoﬁbroblast, and Smooth Muscle Cell
Populations Derived from SFT of the Prostate
Demonstrate NAB2-STAT6 Fusion Proteins
Quantitative RT-PCR failed to identify NAB2-STAT6 fusion
transcripts in the myoﬁbroblastic, ﬁbroblastic, or smooth
muscle cell populations grown from the SFT prostate tissue,736even though the tissue had demonstrated NAB2-STAT6 fusion
transcripts by transcriptome sequencing. Because the quanti-
tative RT-PCR primers used captured only the common
NAB2-STAT6 transcript fusion variants, it was possible that the
fusion transcript(s) may have been missed by quantitative RT-
PCR analysis if other or more than one type NAB2-STAT6
fusion variant was present in the cells. Therefore, protein was
puriﬁed from the SFT prostate tissue and derived myoﬁbro-
blastic, ﬁbroblastic, or smooth muscle cell populations,
immunoblotted, and probed with an antibody against STAT6.
As seen in Figure 4, the SFT prostate tissue demonstrates a
faint band corresponding to wild-type STAT6 (wtSTAT6), as
well as bands at approximately 150 kDa and approximately
100 kDa that correspond to two forms of NAB2-STAT6
fusion proteins, consistent with those reported originally by
Robinson et al.22 Myoﬁbroblasts grown from the SFT prostate
demonstrate equivalent amounts of wtSTAT6 and the
approximately 100-kDa NAB2-STAT6 fusion protein,
whereas ﬁbroblasts express a small amount of wtSTAT6 and
high levels of the approximately 150-kDa NAB2-STAT6
fusion protein. Smooth muscle cells express only trace
amounts of wtSTAT6 but large quantities of the approximately
150-kDa NAB2-STAT6 protein. There is also some evidence
of additional NAB2-STAT6 fusion proteins expressed by the
three derivative cell populations in the 100 to 150 kDa range.
Taken together, these data suggest that the three derivative cell
populations differentially express the NAB2-STAT6 fusion
proteins expressed in the originating SFT prostate tissue, and
that these cell populations may have originated from cells
preferentially expressing different forms of the fusion protein.
TGFb and CXC-Type Chemokines Mediate Myoﬁbroblast
Phenoconversion of Primary Fibroblasts from SFT of
Prostate
We had previously shown that resident primary ﬁbroblasts
from the periurethral prostate could undergo myoﬁbroblastajp.amjpathol.org - The American Journal of Pathology
Complex Composition of Prostate SFTphenoconversion on exposure to the canonical proﬁbrotic
protein, TGF-b, or to the noncanonical proﬁbrotic proteins
CXCL5, CXCL8, and CXCL12 in the absence of TGF-b.27
We therefore tested whether ﬁbroblasts grown from the SFT
tissue would similarly phenoconvert. As shown in Figure 5,
ﬁbroblasts cultured from the SFT tissue expressed vimentin
and calponin, and weakly expressed collagen I, consistent
with a ﬁbroblast phenotype. When treated for 48 hours with
5 ng/mL TGF-b or with CXCL5, CXCL8, or CXCL12, each
at a concentration of 100 pmol/L, the cells coexpressed
vimentin, a-SMA, and collagen, but ceased expression of
calponin, consistent with a myoﬁbroblast phenotype.
Therefore, the ﬁbroblasts cultured from the SFT tissues
demonstrated a phenotype consistent with normal, resident
prostate stromal ﬁbroblasts that undergo myoﬁbroblast
phenoconversion on exposure to proﬁbrotic stimuli.Discussion
SFTs involving the prostate are extremely rare, with only
isolated cases reported in the literature. Prostatic SFTs have
been reported in patients ranging in age from 21 to 75 years,
and the most common clinical ﬁndings include urinary reten-
tion, urinary frequency, dysuria, constipation, incontinence,
and groin pain. These tumors demonstrate a broad sizeFigure 5 SFT ﬁbroblasts undergo myoﬁbroblast differentiation on exposure to
treated with PBS or proﬁbrotic proteins TGFb (5ng/ml), CXCL5, CXCL8, CXCL12 (
centration of 100 pmol/L or 1000 pmol/L each (as indicated). Cell nuclei were c
spindle-shaped morphology and weakly express collagen I, but not a-SMA, whe
morphology and coexpress a-SMA and collagen, indicative of myoﬁbroblast phen
morphology and express vimentin, whereas those treated with proﬁbrotic prote
a-SMA. Bottom row: Cells treated with PBS exhibit a spindle-shaped morpholo
demonstrate a more compact morphology and express a-SMA, but not calponin.
due to exposure to proﬁbrotic proteins.
The American Journal of Pathology - ajp.amjpathol.orgdistribution, ranging from 5 g to >100 g.1,21 Indeed, the
prostate harboring the SFT described here weighted >700 g.
The malignant potential of SFT is difﬁcult to predict, and little
is known regarding the underlying biology of these tumors.
This suggests that SFTs merit further study to predict malig-
nant potential and develop appropriate treatment strategies.
The studies described here demonstrate that SFTs of the
prostate can be complex tumors at the cellular level. In
common with SFTs involving the more common sites, the
histopathological assessment demonstrated the presence of
bland spindle cells intermixed with collagen and distributed
in hypercellular and hypocellular areas. Immunohisto-
chemical examination demonstrated that the tumor cells
expressed bcl-2, CD99, and CD34, and focally expressed
desmin and progesterone receptor. Also in common with
SFTs involving other sites, the tumor examined here was
characterized by a NAB2-STAT6 fusion structurally similar
to the most common form of NAB2-STAT6 fusions
described for this tumor type.22,23 Thus, by all deﬁnitions,
the greatly enlarged prostate examined in this study was
dominated by a highly proliferative SFT.
The cellular composition of the prostatic SFT described
in this paper was complex. Three mesenchymally derived
cell typesdﬁbroblasts, myoﬁbroblasts, and smooth muscle
cellsdsurvived explantation and exhibited at least limited
growth in vitro. Moreover, these three derivative cellproﬁbrotic stimuli. Fibroblastic cells cultured from the prostatic SFT were
100 pmol/L each), or the three CXC-type chemokines combined at a con-
ounterstained with DAPI (blue). Top row: Cells treated with PBS exhibit a
reas those treated with proﬁbrotic proteins demonstrate a more compact
oconversion. Middle row: Cells treated with PBS exhibit a spindle-shaped
ins demonstrate a more compact morphology and coexpress vimentin and
gy and express calponin, whereas those treated with proﬁbrotic proteins
These staining patterns are consistent with myoﬁbroblast phenoconversion
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Gharaee-Kermani et alpopulations differentially expressed the NAB2-STAT6
fusion proteins expressed in the originating SFT prostate
tissue, and therefore share identify with the originating SFT
tumor. Interestingly, the three derivative cell populations
demonstrated differential expression of the NAB2-STAT6
fusion protein variants, suggesting that these cell populations
may have originated from cells preferentially expressing
different forms of the fusion protein. This implies that,
despite the rather bland spindle cell morphology often
described for SFTs, these tumors can be genetically and
phenotypically quite complex, which may, in turn, contribute
to the heterogeneous behavior of these tumors in vivo.
As noted above, the SFT prostate examined here was
quite large and weighted approximately 700 g at the time of
resection. Clearly, the cellular composition of this tumor
was highly proliferative in order for the tumor to reach this
size. Our studies suggest that, of the three derivative cell
types identiﬁed in this tumor, the ﬁbroblastic cells were the
most proliferative and were capable of continuous doublings
in culture. This suggests that the ﬁbroblastic component of
this prostatic SFT may have been the proliferative tumor
component in vivo. Moreover, studies presented here
demonstrate that the ﬁbroblastic SFT component readily
underwent myoﬁbroblast phenoconversion on exposure to
proﬁbrotic stimuli, such as TGF-b or CXC-type chemo-
kines, suggesting that the myoﬁbroblastic component of the
SFT may have arisen continuously from the proliferative
ﬁbroblastic component. What accounts, then, for the abun-
dant smooth muscle component cultured from the SFT?
Neither ﬁbroblasts nor myoﬁbroblasts have been shown to
differentiate into smooth muscle cells. However, mesen-
chymal stem/stromal cells (MSCs), a type of mesenchymal
progenitor cell, have been show to differentiate into both
ﬁbroblasts and smooth muscle cells.32,33 Moreover, there is
recent evidence that ex vivo cultured MSCs and ﬁbroblasts
are sometimes indistinguishable (31), suggesting that the
ﬁbroblastic cells cultured from the SFT may have included
MSCs. The lack of deﬁnitive molecular markers prevents
the certain identiﬁcation of MSCs in the SFT reported
here.34 However, an intriguing possibility is that MSCs in
this SFT might account for the extremely large size of the
tumor mass and for the ability of MSCs/ﬁbroblasts isolated
from this tumor to proliferate continually in culture.
Conclusions
We report the ﬁrst study to our knowledge showing that
SFTs of the prostate can comprise a mixed population of
ﬁbroblast, myoﬁbroblast, and smooth muscle cell types. The
highly proliferative component demonstrated a ﬁbroblastic
phenotype that readily underwent myoﬁbroblast differenti-
ation on exposure to proﬁbrotic stimuli. Consistent with
other recent studies, the prostatic SFT demonstrated NAB2-
STAT6 fusion proteins as did the derivate cell populations.
The results of these studies suggest that benign and malig-
nant prostatic tumors of mesenchymal origin may be738distinguished at the molecular and cellular levels, and that
delineation of such deﬁning characteristics may help eluci-
date the etiology and prognosis of such tumors.References
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